Searched for
ALOK SONIG
US drug maker Baxter opens R&D centre in AhmedabadBaxter said the Ahmedabad R&D centre will help the company to accelerate innovation in generic and differentiated injectable pharmaceutical...- Dr Reddy’s top hand Alok Sonig quitsSonig handled challenging roles during his six-year tenure at the company founded and named after scientist-entrepreneur late K Anji Reddy.
- Dr Reddy’s Labs climbs after launch of generic Sevelamer carbonate tablets in USShares of the company opened at Rs 2,406 and touched a high and low of Rs 2,415 and Rs 2,355, respectively, in trade so far.
- Buy Dr. Reddy's Laboratories, target Rs 2715.0 : Siddharth BhamreBuy Dr. Reddy's Laboratories Ltd. at a price target of Rs 2715.0 and a stop loss at Rs 2560.0 from entry point
- Sell Dr. Reddy's Laboratories, target Rs 2577.0 : Deen Dayal InvestmentSell Dr. Reddy's Laboratories Ltd. at a price target of Rs 2577.0 and a stop loss at Rs 2650 from entry point
- Dr Reddy's joins hands with Gland Pharma to market 8 ANDAs in USDr Reddy's is developing its injectable business and recently launched Paricalcitol injection, a therapeutic equivalent generic version of ...
- Dr. Reddy’s buys eight ANDAs from Teva for $350 millionDr. Reddy’s said the acquisition of ANDAs is contingent on closing of the Teva generics transaction and approval by the US Federal Trade Co...
- Dr Reddy's buys 6 OTC brands from US-based Ducere PharmaDr Reddy's will build upon the sales and marketing efforts for these brands and continue to focus on their expansion into existing and new ...
- Dr Reddy's picks Alok Sonig to lead North America generics businessIn a top level reshuffle, drug major Dr Reddy's Laboratories appointed Alok Sonig as Executive Vice President & Head for its generics busin...
- Dr Reddy's rejigs top deck as North America head quitsVora will be replaced by Alok Sonig, who is currently responsible for the Indian market and is a member of the management council at the co...
- Dr Reddy’s Laboratories eyes in-licensing pacts with European, Japanese firms to spur domestic revenueChief Financial Officer Saumen Chakraborty confirmed the ongoing talks with global firms for in-licensing agreements, but refused to divulg...
- Dr Reddy's to market three Amgen drugs in IndiaDr Reddy's Laboratories today said it has inked a pact with US-based biotechnology firm Amgen to market its three drugs.
- AstraZeneca, Dr Reddy's ink diabetes drug distribution pactBoth Riax and Riax M are trademarks of the AstraZeneca group. Dr Reddy's Laboratories will be distributing the two drugs in India.
- Dr Reddy's launches drug for stroke patientsHyderabad-based firm has partnered with Spain's Ferrer Internacional SA to make Somazina available in India, Dr Reddy's Laboratories Ltd sa...
- Dr Reddy's Laboratories to buy UCB's Indian arm for Rs 800 croreUCB, listed on Euronext Brussels, has operations in nearly 40 countries with revenues of €3.3 billion (about Rs 22,275 crore) in 2014.
- Dr Reddy’s agrees to buy UCB business in India for Rs 800 croreThe deal will help Dr Reddy's strengthen its presence in dermatology, pediatrics and respiratory products, the company said in a statement ...
- NPPA order may not impact much, seeking legal advice: Dr Reddy'sDrug pricing regulator NPPA has fixed the price of 108 non-scheduled formulation packs of 50 anti-diabetes and cardiac medicines.
- Dr Reddy's Laboratories expects 8-10 pc growth in India generics business this fiscalDRL expects its Indian generic market to grow by 8-10% in the current financial year despite challenges such as price erosion due to new dr...
- Ranbaxy gets a reprieve in generic caseThe Delhi High Court has turned down a plea by US pharma major Bristol-Myers Squibb (BMS) to ban India’s Ranbaxy Laboratories from launchin...
Load More- Buy Dr. Reddy's Laboratories, target Rs 2715.0 : Siddharth Bhamre
